Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it?

Publisher： Cambridge University Press

E-ISSN： 1744-134x|12|4|453-470

ISSN： 1744-1331

Source： Health Economics, Policy and Law, Vol.12, Iss.4, 2017-04, pp. : 453-470

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Market size and pharmaceutical innovation

By  

THE RAND JOURNAL OF ECONOMICS, Vol. 46, Iss. 4, 2015-10 ,pp. : 844-871

John Wiley & Sons Inc

Access to resources Recommend Favorite

Did Medicare Induce Pharmaceutical Innovation?

By Acemoglu Daron   Cutler David   Finkelstein Amy   Linn Joshua  

The American Economic Review, Vol. 96, Iss. 2, 2006-05 ,pp. : 103-107

American Economic Association

Access to resources Recommend Favorite

University entrepreneurship and professor privilege

By Frnstrand Damsgaard Erika   Thursby Marie C.  

Industrial and Corporate Change, Vol. 22, Iss. 1, 2013-02 ,pp. : 183-218

Oxford University Press

Access to resources Recommend Favorite

Measuring Open Innovation in The Bio‐Pharmaceutical Industry

By  

CREATIVITY AND INNOVATION MANAGEMENT, Vol. 24, Iss. 1, 2015-03 ,pp. : 4-28

John Wiley & Sons Inc

Access to resources Recommend Favorite

Funding pharmaceutical innovation through direct tax credits

By  

Health Economics, Policy and Law, Vol. 2, Iss. 3, 2007-07 ,pp. : 267-284

Cambridge University Press

Access to resources Recommend Favorite